{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962793",
  "id": "02962793",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250627",
  "time": "0929",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5ftngmx0ghm.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Acquisition Completion & Key Highlights**  \n- **Acquisition Closed**: NSB acquired 100% of Isopogen WA, securing rights to **StemSmart\u2122 stem cell technology**.  \n- **Funding**: Cash balance **~$7.5m** post-placement (previously disclosed).  \n- **Clinical Focus**: **Special Access Program (SAS)** launched for **fistulising Crohn\u2019s disease**; Phase 2 trial data showed **promising efficacy/safety**.  \n- **Market Potential**: Addressable markets include **Crohn\u2019s ($13.8B by 2026)**, **kidney transplants ($7.2B by 2030)**, and **GVHD ($5.3B by 2032)**.  \n\n#### **Governance Changes**  \n- **New Appointments**: Robert McKenzie (Chair) and Paul Fry (Non-Exec Director) joined; granted **5M options each (exercise price: $0.07, 3-year term)**.  \n- **Resignations**: Tony Keating (Exec Director) and Christopher Ntoumenopoulos (Chair) stepped down.  \n\n#### **Omit Forward-Looking Statements & Boilerplate**.  \n\n**Actions**: Monitor progress of SAS program and Phase 2 Crohn\u2019s data. Note dilution risk from director options.",
  "usage": {
    "prompt_tokens": 1691,
    "completion_tokens": 284,
    "total_tokens": 1975,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:48:44.335697"
}